Please login to the form below

Not currently logged in
Email:
Password:

ITP

This page shows the latest ITP news and features for those working in and with pharma, biotech and healthcare.

FDA clears Dova drug for liver-related low blood platelets

FDA clears Dova drug for liver-related low blood platelets

as the rare diseases idiopathic thrombocytopenia (ITP) and acquired severe aplastic anaemia. ... The US biotech says it has Revolade’s territory firmly in its sights, with plans to file for approval in ITP in the second half of the year, and is also

Latest news

  • Rigel and Ultragenyx claim approvals for rare drugs Rigel and Ultragenyx claim approvals for rare drugs

    Rigel and Ultragenyx claim approvals for rare drugs. Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively. ... ITP is a disease caused by low platelet counts that lead to bruising, bleeding and fatigue.

  • Rigel shaken after fostamatinib misses phase III trial target Rigel shaken after fostamatinib misses phase III trial target

    Shares in Rigel Pharmaceuticals fell yesterday after it revealed its lead drug candidate fostamatinib had failed a phase III trial in chronic/persistent immune thrombocytopenia (ITP), a disease leading to reduced ... ITP is an autoimmune disease where

  • CHMP backs orphan drugs Uptravi and Coagadex CHMP backs orphan drugs Uptravi and Coagadex

    new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    Revolade - sold as Promacta in the US - has previously been approved to treat the rare disorder chronic immune thrombocytopenia (ITP) in Europe and is also authorised for both ITP and SAA ... Epstein said recent approvals in SAA and paediatric ITP will

  • Novartis gets FDA nod for rare blood disorder drug Novartis gets FDA nod for rare blood disorder drug

    The FDA has approved Novartis' Promacta for the treatment of children over six with chronic immune thrombocytopenia (ITP), seven years after it was given the nod for adults. ... patients taking concomitant ITP medications were also able to reduce of

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics